Ask AI
ProCE Banner Activity

Insights from HOPA 2025: Incorporating Bispecific Antibodies Into NHL Management

Clinical Thought

Bispecific antibodies are important options for treating relapsed/refractory NHL in both community and academic practice settings. We discuss strategies for incorporating bispecific antibodies into clinical practice and approaches to mitigate treatment-related adverse events to individualize and optimize therapy.

Released: June 26, 2025

Expiration: June 25, 2026

Continue Activity View Activity

Share

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Genentech, a member of the Roche Group.

Genentech, a member of the Roche Group

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

C. Brooke Adams, PharmD, BCOP: consultant/advisor/speaker: Genmab, Johnson & Johnson, Pfizer.

Sarah Profitt, PharmD, BCOP: consultant/advisor/speaker: Blueprint Medicines, Genentech, Lilly, Rigel.